-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-519814-29-00
4
2025-09-12
Advanced or Metastatic Non-small Cell Lung Cancer
-
2023-509829-52-00
6
2025-09-01
Macular edema
-
2025-522126-13-00
1
2025-08-29
Cold Induced Urticaria
-
2024-514296-17-00
3
2025-08-05
Attention deficit hyperactivity disorder
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2025-520705-12-00
4
2025-06-24
Colitis Ulcerative
-
2023-509055-14-00
4
2025-06-17
myelodysplastic neoplasia (MDS)
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2023-509391-42-00
11
2025-06-02
Chron's Disease
-
2024-516605-23-00
5
2025-05-12
relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
-
2024-515593-27-00
5
2025-05-08
relapsed or refractory mantle cell lymphoma (R/R MCL)
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2024-511037-35-00
4
2025-01-31
Cyclosporine A is a well known medication and is used to prevent rejec
-
2024-514303-34-00
1
2024-12-18
Acute Incomplete Cervical Spinal Cord Injury
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB